Small molecules that target the adrenergic family of G protein-coupled receptors (GPCRs) show promising therapeutic efficacy for the treatment of various cancers. Herein, we report that human colon cancer cell line SW480 expresses low-density functional α 1B -adrenergic receptors (ARs) as revealed by label-free dynamic mass redistribution (DMR) signaling technology and confirmed by quantitative reverse-transcriptase polymerase chain reaction analysis. Remarkably, while endogenous α 1B -ARs are not detectable via either [ 3 H]-prazosin binding analysis or phosphoinositol hydrolysis assays, their activation leads to robust DMR and enhanced cell viability. We provide pharmacological evidence that stimulation of α 1B -ARs enhances SW480 cell viability without affecting proliferation, whereas stimulating β-ARs diminishes both viability and proliferation of SW480 cells. Our study illustrates the power of label-free DMR technology for identifying and characterizing low-density GPCRs in cells and suggests that drugs targeting both α 1Band β-ARs may represent valuable small molecule therapeutics for the treatment of colon cancer.
Introduction
Catecholamines play a key role in regulating multiple physiological responses, with the overarching goal of enhancing organism survival. However, in certain instances, prolonged catecholamine exposure produces detrimental effects on target organs that lead to cardiovascular disease (e.g. congestive heart failure, hypertension, cardiac arrhythmias and renal failure) and/or psychiatric disorders (e.g. post-traumatic stress disorder and hyperactivity disorders). Although the molecular mechanisms that mediate these detrimental effects remain to be fully understood, it is well appreciated that chronic adrenergic receptor (AR) activation ultimately leads to deleterious alterations in cell morphology (Lefkowitz et al, 2000; O'Connell et al, 2006; Catapano et al, 2007) .
JPET #237255 models, chronic activation of α 1A -ARs reduces cancer incidence and prolongs lifespan, whereas chronic α 1B -AR activation typically produces deleterious effects on multiple organ systems (Collette et al, 2014; Wang et al, 2000; Zuscik et al, 2000; Papay et al, 2002; Doze et al, 2009 ).
As such, understanding the effects of chronic α 1 -AR activation in specific cancer subtypes is essential.
Our laboratory studies macromolecular complexes formed by distinct α 1 -AR subtypes and how complex architecture influences α 1 -AR signaling and physiological function. We recently showed that α 1 -AR subtypes associate with selective intracellular molecular scaffolds that dictate their pharmacodynamic and signaling characteristics (Camp et al, 2015; Lyssand et al, 2010; Lyssand et al, 2008) . Interestingly, proteomic screening indicates cell-type specific α 1 -AR:PDZprotein complexes are formed in human SW480 colon cancer cells, suggesting α 1 -ARs may couple to non-canonical, G-protein independent signal transduction mechanisms in this cell line (Camp et al, 2015) . Thus, we used label-free dynamic mass redistribution assays to pharmacologically identify endogenous α 1 -AR subtypes functionally expressed in SW480 colon carcinoma cells, thereby facilitating their examination as potential anti-neoplastic drug targets.
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to adding agonist to ensure that equilibrium between antagonist and receptor had been reached, during which baseline DMR measurements were recorded. All compounds were added using a Sorenson Biosciences 96-well Benchtop Pipettor. Agonist DMR responses were recorded for 1 hr.
Raw data were exported to Microsoft Excel using Epic Analyzer Software, and then imported into GraphPad Prism software to calculate agonist (potency, intrinsic activity) and antagonist (affinity) properties. Agonist concentration-response curves were fit using variable slope nonlinear regression to determine potency (EC 50 ) and Hill slope. Y-axis values on raw DMR data and agonist DMR concentration-response curves represent the shift in light wavelength in picometers (pm) as a result of dynamic mass redistribution (DMR). Schild Plot analyses were performed when appropriate using a method derived from that first described in (Arunlakshana and Schild, 1959) . Schild data were calculated for each experimental n (each having 4 replicates), and final Schild plots were calculated as the mean ± SEM of each experimental value. Schild plots were fit using linear regression analysis. Non-linear regression analysis was also used to determine if antagonist Schild slopes were significantly different than 1. Apparent affinity (pK B ) was calculated using the equation pK B = log (DR-1) -log [B] . Control experiments were performed demonstrating antagonists used in this study did not stimulate significant DMR responses (see Supplemental Figure 1 ).
Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) assays
Total RNA was isolated from SW480 cells using NucleoSpin RNA isolation kit according to manufacturer's instructions (Macherey-Nagel). One-step qRT-PCR reactions were carried out in a final volume of 20 µL that included: 2 µL of template RNA (25 ng final concentration), 0.8 µL forward and reverse primer (10 µM final concentration), 0.4 µL ROX reference dye, 10 µL of 2x one step SYBR RT-PCR Buffer, and 5.2 µL of RNase free H 2 O using the One Step SYBR PrimeScript RT-PCR kit (Clontech). Primers used for qRT-PCR analysis were: α 1A Forward: 5'-TGCCAGATCAACGAGGAGC-3', Reverse: 5'-GGCGTTTTTCCGATGGATGC-3'; This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on February 14, 2017 as DOI: 10.1124 at ASPET Journals on March 6, 2017 jpet.aspetjournals.org Downloaded from α 1B Forward: 5'-CTTTCACGAGGACACCCTTAGC-3', Reverse: 5'-GCCCAACGTCTTAGCTGCTT-3'; α 1D Forward: 5'-CTCCAGCCTGTCGCACAAG-3', Reverse: 5'-TGTAGTCGGCCAATTCGTAGG-3';
β2 Forward: 5'-TGGTGTGGATTGTGTCAGGC-3', Reverse: 5'-GGCTTGGTTCGTGAAGAAGTC-3';
APRT Forward: 5'-GGCCGCATCGACTACATCG-3', Reverse: 5'-CTCAGCCTTCCCGTACTCC-3'.
qRT-PCR reactions were performed using the following protocol: 42 o C for 5 min; 95 o C for 5 sec; 60 o C for 20 sec. Melt curve data were collected from 60 o C to 95 o C at a ramping rate of 0.2 o C per second. qRT-PCR reactions were performed in quadruplicate on a Stratagene Mx3000 Real Time PCR system. Relative expression values of each genes of interest were normalized to the expression value of housekeeping gene adenine phosphoribosyltransferase (APRT).
Radioligand binding assays
Cell membranes were prepared from cultured SW480 cells via scraping and polytron grinding 3 times for 30 sec. Lysates were resuspended in ice cold phosphate buffered saline (PBS). Protein concentration was determined with an Eppendorf D30 BioPhotometer. 100 µL of PBS containing 100 ug of resuspended cell lysates were incubated with 100 µL of varying concentrations of [ 3 H]prazosin for 30 min at 37C with gentle shaking, in the absence (representing Total [ 3 H]-prazosin bound) or presence of 100 µM of the non-selective α-AR antagonist phentolamine (representing Non-specific [ 3 H]-prazosin bound). Samples were then subjected to Brandel vacuum filtration (Brandel, Gaithersburg, MD) . Filters were incubated with 5 mL liquid scintillation fluid and counted with a Tri-Carb 2200 CA liquid scintillation analyzer (Packard Instrument Co. Inc., Rockville, MD). Data were converted from CPM to fmol/mg protein (http://www.graphpad.com/quickcalcs/radcalcform/), and specific bound was calculated as Total Bound -Non-Specific Bound. Specific bound data were fit with one-site specific binding saturation analysis using GraphPad Prism 6 software. Data are expressed as mean ± SEM. This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on February 14, 2017 as DOI: 10.1124 at ASPET Journals on March 6, 2017 jpet.aspetjournals.org
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Phosphoinositol hydrolysis assays SW480 cells were pre-labeled with 1 mCi/mL [ 3 H]-myo-inositol. After 48 hrs, cells were stimulated with 100 µM phenylephrine for 1 h in HBSS buffer + 10 mM LiCl. Total inositol phosphates were purified via Dowex ion exchange chromatography using the method described in (Lyssand et al, 2008) . Data were analyzed with GraphPad Prism 6 software and expressed as mean ± SEM.
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Results
One study has examined adrenergic receptor (AR) expression and function in SW480 cells (Masur et al, 2001) . Specifically, using flow cytometry and primary antibodies targeting AR subtypes, this study suggested that SW480 cells express α 2 and β-ARs, and little to no α 1 -ARs.
To confirm this finding, we subjected SW480 cells to label-free dynamic mass redistribution assays, which measures agonist-stimulated changes in cell shape as a functional output. This (Table 1) . 5-HT ( Fig. 1E ) and histamine (data not shown) produced no significant DMR responses, suggesting members of these essential GPCR receptor families are not endogenously expressed by SW480 cells.
Unexpectedly, the α 1 -AR selective agonist phenylephrine stimulated positive DMR responses with higher intrinsic activity (IA = 0.68) than both clonidine and isoproterenol, suggesting that functional α 1 -ARs are present in SW480 cells, in direct contrast to the findings of previous studies (Masur et al, 2001) . This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on February 14, 2017 as DOI: 10.1124 at ASPET Journals on March 6, 2017 jpet.aspetjournals.org
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Because DMR assays are thought to measure the summation of all cell signaling events, the possibility exists that the observed phenylephrine effects are a result of non-α 1 -AR signaling mechanisms. Phenylephrine has been reported to activate β-ARs in human vascular beds (Torp et al, 1985) , rabbit left ventricle (Wagner et al, 1974) and guinea-pig ventricles (Chess-Williams et al, 1990) , depending on the relative density of α-versus β-ARs expressed. Thus, we assayed the efficacy of AR subtype-selective antagonists to block phenylephrine-stimulated DMR responses.
If the observed phenylephrine DMR events are occurring via direct α 1 -AR stimulation, we expect α 1 -AR antagonists to inhibit phenylephrine responses at concentrations in the range of their reported nanomolar affinities. Saturating concentrations of the β-AR antagonist propranolol produced no significant changes in the phenylephrine DMR concentration response curve ( Fig.   2A ), nor did the α 2 -AR antagonist rauwolscine ( Fig. 2B ), suggesting that phenylephrine DMR responses are not a result of β or α 2 -AR receptor activation. By sharp contrast, pre-treating cells for 1 h with 100 nM of the α 1 /α 2 -AR irreversible antagonist phenoxybenzamine abolished phenylephrine DMR responses ( Fig. 2C) . Likewise, the competitive α 1 /α 2 -AR antagonist phentolamine produced progressive rightward shifts in phenylephrine concentration-response curve with successive half-log molar increments ( Fig. 2D ). Phenylephrine potencies in the absence and presence of phentolamine were determined and used to calculate phentolamine affinity using Schild regression analysis (Arunlakshana and Schild, 1959) . Phentolamine inhibited phenylephrine DMR responses with pA 2 = -6.93, or 117 nM ( Fig. 2E , Table 2 ), which is within the range of previously reported values for binding the α 1B -AR subtype (Morrow et al, 1986; Hong et al, 2005; Bavadekar et al, 2008) .
We next assayed the affinity of the quinazoline α 1 -AR selective antagonists doxazosin ( Table 2 ). The affinities for terazosin and doxazosin are consistent with previously reported affinity values for antagonizing α 1 -AR stimulated contractions of the rabbit (Martin et al, 1997) and human prostate (Muramatsu et al, 1998; Kenny et al, 1996) . However, the observed prazosin DMR affinity is appreciably lower than what is reported in isolated tissue in vitro contraction assays examining the three α 1 -AR subtypes (Docherty, 2010) . Rather, our observed prazosin affinity value is within the range of the elusive "α 1L -adrenoceptor", or lowaffinity α 1 -AR prazosin binding site previously documented to be present in dog saphenous vein (Muramatsu et al, 1990) , rat small mesenteric artery (Stam et al, 1999) , rabbit urinary tract (Van der Graaf et al, 1997), rat portal vein (Digges et al, 1983) and rat vas deferens (Muramatsu et al, 1996) . Thus, the lack of effect of β and α 2 -AR antagonists, and the pronounced inhibition of phenylephrine DMR responses by mixed α 1 /α 2 -AR and α 1 -AR selective antagonists indicates SW480 cells express functional α 1 -ARs.
We next sought to identify the specific α 1 -AR subtype(s) expressed by comparing the ability of various α 1 -AR subtype selective antagonists to inhibit phenylephrine DMR responses. The antagonists tested included tamsulosin (α 1A/D -AR selective), 5-methylurapidil and niguldipine (α 1A -AR selective), cyclazosin (α 1B -AR selective) and BMY7378 (α 1D -AR selective). All antagonist functional data are compiled in Table 2. BMY7378 inhibited DMR responses with pA 2 = -6.87, or 134 nM ( Fig. 4A,B ), which is significantly lower than previously reported BMY 7378 functional affinities for inhibiting α 1D -AR mediated contraction of rat (Goetz et al, 1995; Kenny et al, 1995; Indra et al, 2002; Cleary et al, 2005) or mouse thoracic aorta (Yamamoto et al, 2001) , and more indicative of an α 1A or α 1B affinity for this antagonist. Accordingly, the α 1A/D -AR antagonist tamsulosin blocked phenylephrine stimulated DMR ( Fig. 4C ) with significantly lower apparent affinity (1 µM tamsulosin pK B = -6.83 ± 0.08) than previously reported tamsulosin pA 2 values for blocking the α 1A or α 1D -AR subtypes (Noble et al, 1997) . The lack of α 1A -AR contribution to phenylephrine with high affinity strongly suggests the α 1A and α 1D subtypes do not functionally contribute to phenylephrine responses. Conversely, the α 1B -AR selective antagonist cyclazosin potently inhibited phenylephrine responses with pA 2 = -8.37, or 4.26 nM (Fig. 4F, G) , consistent with reported affinities for blocking α 1B -AR mediated contraction of rabbit thoracic aorta (Marucci et al, 2005) . Given the α 1B -AR antagonist cyclazosin produced the most potent inhibition of phenylephrine DMR responses in SW480 cells, we hypothesize SW480 cells express predominantly the α 1B -AR subtype.
Label-free DMR pharmacological results were subsequently validated with quantitative reverse-transcriptase polymerase chain reaction (qPCR) assays. Internal primers directed against individual α 1 -AR subtypes and the β2-AR were used to measure relative mRNA concentrations expressed as cycle threshold (CT) fold. All values were compared to adenine phosphoribosyltransferase (APRT) levels as a reference house-keeping gene. As shown in Figure   5A , α 1B -AR mRNA levels were 2.53 ± 0.09 fold greater than APRT, whereas α 1A -AR (0.02 ± 0.06) and α 1D -AR (6 x 10 -4 ± 0.28) mRNA levels were barely detectable. β2-AR mRNA levels (0.09 ± 0.04) were greater than α 1A -and α 1D -AR, yet significantly lower than α 1B -AR.
Thus, SW480 cells produce relatively high levels of α 1B -AR mRNA and robust phenylephrine-stimulated label-free DMR responses inhibited by the α 1B -AR selective antagonist cyclazosin. Yet, α 1 -ARs are reported as minimally detectable in previous flow cytometry assays (Masur et al, 2001) . To clarify this discrepancy, we quantified endogenous α 1B -AR functional receptor density with [ 3 H]-prazosin radioligand binding and phosphoinositol hydrolysis assays.
As a positive control we included SW480 cells transfected with N-terminal SNAP-epitope tagged α 1B -ARs. SNAP protein gels demonstrated 3 ug of SNAP-α 1B -AR cDNA was optimal for ensuring SW480 cell viability and maximal SNAP-α 1B -AR protein levels (Fig. 5B , denoted with arrow at ~ 76.6 kDa). Remarkably, we did not detect significant levels of endogenous α 1B -AR binding sites (<10 fmol/mg protein) in SW480 cell lysates with [ 3 H]-prazosin saturation radioligand binding assays, whereas transfecting SNAP-α 1B -AR induced a robust increase in receptor density (Bmax to 59.3 ± 10.7 fmol/mg protein, Fig. 5C ). Phosphoinositol hydrolysis assays produced equivalent results (Fig. 5D ). Specifically, application of 100 µM phenylephrine did not generate significant increases in WT SW480 cellular inositol phosphate levels, yet produced a 62.1% increase in inositol phosphate formation in SW480 cells transfected with SNAP-α 1B -AR. Congruent with this finding, maximal phenylephrine-stimulated DMR responses were enhanced by 25.8% in SW480 cells when transfected with SNAP-α 1B -AR (Fig. 5E ). Taken together, these data demonstrate that SW480 cells express low levels of functional α 1B -ARs that are undetectable with radioligand binding and reductionist functional assays, but are robustly detectable with label-free DMR assays.
While it is has been shown that AR stimulation induces migration of cultured SW480 cells (Masur et al, 2001) , this study used norepinephrine as the adrenergic agonist and thus the AR subtype(s) involved remain unclear. With the discovery that SW480 cells express low level of functional α 1B -ARs, we sought to delineate the effect of β and α 1 -ARs stimulation on SW480 cell viability and proliferation. β-AR stimulation with isoproterenol produced a dose-dependent decrease in both cell viability and proliferation ( Figure 6A ). Note that the anti-proliferative effects of isoproterenol were marginally greater than its anti-viability effects. Conversely, α 1 -AR stimulation with phenylephrine produced a striking increase in cell viability, with no significant effects on cell proliferation ( Figure 6B ). The pro-survival effects of phenylephrine were antagonized by the α 1 -AR antagonists terazosin, cyclazosin, phenoxybenzamine and phentolamine ( Figure 6C) . These results show that SW480 cells express low densities of functional α 1B -ARs, that when activated, are pro-survival.
Discussion
With the ongoing and increasing usage of small molecules targeting adrenergic signaling mechanisms for the treatment of cardiovascular disease, central nervous system disorders and numerous other indications, understanding whether these medicines also influence tumor growth and/or metastasis is of critical importance. Accordingly, identifying subtypes of adrenergic receptors (ARs) expressed by specific cancer cells, characterizing the action of small molecules targeting this receptor family, and their resulting effect on tumor cell fate will provide critical information that might drive patient-specific pharmacotherapy. In this study we illustrate the inherent power of label-free dynamic mass redistribution signaling technology to identify low density, yet highly-functional ARs in SW480 carcinoma cancer cells. Moreover, to the best of our knowledge, our study represents the first to combine label-free DMR assays with Schild regression analysis of antagonist affinities to facilitate pharmacological characterization of cancer cell specific expression of endogenous GPCR subtypes. Based on these results, we provide evidence that antagonists targeting both α 1B -AR and β-AR may significantly effect cancer cell fate.
The effects of chronic AR stimulation on human health and disease have been extensively studied and documented. Thus far, the overwhelming majority of the data indicates chronic β-AR stimulation produces negative outcomes on cancer prognosis. Epidemiological data compiled from breast cancer outcomes of patients on chronic β-blocker therapy had a 57% reduced risk of metastasis and 71% reduction in mortality after 10 years (Powe et al, 2010) . A subsequent study discovered brain metastasis derived from breast cancer cells have increased β2-AR mRNA and protein expression levels, and exhibit enhanced cell proliferation and migration (Choy et al, 2016) .
Chronic β-AR activation induced by stress promotes colon cancer metastasis (Zhao et al, 2015) , possibly through trans-activation of the EGFR-Akt/ERK pathway (Chin et al, 2016) . Accordingly, β-AR blockade has been shown to be an effective treatment in experimental models of colon cancer (Barbieri et al, 2015; Sorski et al, 2016) and reduces the incidence of colon cancer in human populations (Chang et al, 2015) . Contrary to these findings, we found β-AR activation decreased SW480 cell viability and proliferation, similar to what has been reported in cardiomyocytes during heart failure, where prolonged β-AR stimulation leads cell death, fibrosis and adverse remodeling (reviewed in Lefkowitz et al, 2000) .
Significantly less information exists on the role of α 1 -AR activation in cancer outcomes.
Studies investigating the effects of chronic α 1 -AR stimulation on cell survival from cardiovascular studies provide valuable insights (Furberg et al, 2002) . A major revelation of the groundbreaking Anti-Hypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) was the increased incidence of deleterious cardiovascular events in the doxazosin-This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on February 14, 2017 as DOI: 10.1124 at ASPET Journals on March 6, 2017 jpet.aspetjournals.org Downloaded from treatment arm, forcing an early termination of this portion of the study (Piller et al, 2002) . This single observation has significantly diminished the use of α 1 -AR antagonists for hypertension, heart failure and other cardiovascular diseases. Subsequent basic science studies showed that α 1 -AR stimulation inhibits apoptosis in in vitro and in vivo and enhances ischemic preconditioning in In summary, we leveraged the power of label-free DMR signaling technology to identify and characterize low-density α 1B -ARs previously undetectable with traditional experimental This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on February 14, 2017 as DOI: 10.1124 at ASPET Journals on March 6, 2017 jpet.aspetjournals.org Downloaded from approaches used to quantify GPCR functional expression levels in cell culture (i.e. as measured by flow cytometry, radioligand binding or reductionist functional assays), which when activated, increase the survival of human SW480 colon carcinoma cells. To our knowledge, this study is the first to examine the effects of α 1B -AR stimulation on human colon carcinoma cell fate. Thus, label-free DMR should prove useful for characterizing membrane signaling proteins functionally expressed on specific carcinoma cell types, thereby facilitating their investigation as potential anti-neoplastic targets using available therapeutic agents, or to predict the side effects of concurrently-used medications on tumor cell outcome. As health-care systems move towards the era of precision medicine, the translational advantages of label-free technology provides a unique opportunity to drive patient-specific pharmacotherapy. Our discovery that α 1B -ARs are prosurvival in SW480 colon carcinoma cells may have relevance for the increasing number of patients taking α 1 -AR antagonists for benign prostatic hypertrophy, post-traumatic stress disorder and/or cardiovascular disease. Thus, further investigation into the effects of α 1 -AR stimulation on colon carcinoma cell fate are warranted.
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This article has not been copyedited and formatted. The final version may differ from this version. -3.21 ± 0.1 (10 µM) -6.87 ± 0.47 1.06 ± 0.01 Table 2 . Pharmacological values used for α 1 -AR subtype selective antagonist Schild regression analyses. Phenylephrine stimulated concentration-response curves were calculated for stimulating dynamic mass redistribution (DMR) responses in SW480 cells. Log molar agonist potencies (pEC 50 ) were calculated using the time at which peak DMR response was observed in the absence and presence of various α-AR antagonists (concentration of antagonist used shown in brackets for each phenylephrine pEC 50 value). Agonist potencies were subsequently used to calculate antagonist affinity and slope via Schild regression analysis. All data were analyzed with GraphPad Prism and are expressed as mean ± SEM of 2-4 independent experiments performed with 4 replicates. ** indicates calculated Schild slope is significantly different than unity as determined by nonlinear regression analysis including extra sum-of-squares F test to hypothetical value of 1. ^^ indicates agonist concentration-response curve Hill slope is <1 as determined by non-linear regression curve four parameter variable slope analysis. ND = not determined.
